Dr Lisa Alcock wins Tour de Cure funding for cancer research
Dr Alcock has received an Early Career Research Grant from Tour de Cure, which funds cancer research by outstanding researchers who are within five years of being awarded their PhD.
Tour de Cure is a charity founded in 2007 to promote the prevention or control of human cancers.
Dr Alcock is developing the first ever targeted therapy for ALT (alternative lengthening of telomeres) positive osteosarcoma – a childhood cancer that is the most common type of bone cancer in adolescents and has low survival rates.
“I am very grateful to receive this Tour de Cure Early Career Research grant as the Chief Investigator, as it marks my first major grant success,” said Dr Alcock.
“Receiving this grant means I can gain valuable experience in leading a drug discovery campaign and generate impactful research that can be used to apply for future funding to not only accelerate our research to the next level, but assist in my career development.”
Dr Alcock has received an Early Career Research Grant from Tour de Cure, which funds cancer research by outstanding researchers who are within five years of being awarded their PhD.
Tour de Cure is a charity founded in 2007 to promote the prevention or control of human cancers.
Dr Alcock is developing the first ever targeted therapy for ALT (alternative lengthening of telomeres) positive osteosarcoma – a childhood cancer that is the most common type of bone cancer in adolescents and has low survival rates.
“I am very grateful to receive this Tour de Cure Early Career Research grant as the Chief Investigator, as it marks my first major grant success,” said Dr Alcock.
“Receiving this grant means I can gain valuable experience in leading a drug discovery campaign and generate impactful research that can be used to apply for future funding to not only accelerate our research to the next level, but assist in my career development.”
